Literature DB >> 11095840

Rotavirus Vaccines: Current Controversies and Future Directions.

.   

Abstract

Rotaviruses are the most important cause of pediatric gastroenteritis worldwide. In August 1998, a new rotavirus vaccine was licensed for general use in the United States. However, 14 months later, the vaccine was withdrawn from the market because of serious gastrointestinal side effects. This paper discusses the need for a rotavirus vaccine, the development of the first rotavirus vaccine, and the safety issues that led to the recall of that vaccine.

Entities:  

Year:  2000        PMID: 11095840     DOI: 10.1007/s11908-000-0090-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  41 in total

1.  Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate.

Authors:  G L Barnes; J S Lund; L Adams; A Mora; S V Mitchell; A Caples; R F Bishop
Journal:  J Paediatr Child Health       Date:  1997-08       Impact factor: 1.954

2.  Cost-effectiveness analysis of a rotavirus immunization program for the United States.

Authors:  A W Tucker; A C Haddix; J S Bresee; R C Holman; U D Parashar; R I Glass
Journal:  JAMA       Date:  1998-05-06       Impact factor: 56.272

3.  Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants.

Authors:  J Joensuu; E Koskenniemi; T Vesikari
Journal:  Pediatr Infect Dis J       Date:  1998-04       Impact factor: 2.129

4.  A one-year virological survey of acute intussusception in childhood.

Authors:  J C Nicolas; D Ingrand; B Fortier; F Bricout
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

Review 5.  The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.

Authors:  H F Clark; P A Offit; R W Ellis; J J Eiden; D Krah; A R Shaw; M Pichichero; J J Treanor; F E Borian; L M Bell; S A Plotkin
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

6.  Characterization of human rotavirus genotype P[8]G5 from Brazil by probe-hybridization and sequence.

Authors:  A A Alfieri; J P Leite; O Nakagomi; E Kaga; P A Woods; R I Glass; J R Gentsch
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  The protective effectiveness of natural rotavirus infection in an American Indian population.

Authors:  L H Moulton; M A Staat; M Santosham; R L Ward
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

8.  Cost-effectiveness analysis of a rotavirus immunization program for the United States.

Authors:  J C Smith; A C Haddix; S M Teutsch; R I Glass
Journal:  Pediatrics       Date:  1995-10       Impact factor: 7.124

9.  Relative importance of rotavirus-specific effector and memory B cells in protection against challenge.

Authors:  C A Moser; S Cookinham; S E Coffin; H F Clark; P A Offit
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children.

Authors:  W J Rodriguez; H W Kim; J O Arrobio; C D Brandt; R M Chanock; A Z Kapikian; R G Wyatt; R H Parrott
Journal:  J Pediatr       Date:  1977-08       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.